We are glad to share with you that select PCM content is now available in Chinese
We are glad to present a brief report on the progress of Precision Cancer Medicine (PCM) in 2021
Starting from July 2021, AME Publishing Company is formally recognized a publisher member of Committee on Publication Ethics (COPE) and over 60 AME-published journals become a member of Committee on Publication Ethics (COPE), as part of AME’s commitment to best practice in scholarly publishing. Precision Cancer Medicine (PCM) is among the list of COPE membership.
On June 26, 2021, we received the good news from Elsevier that Precision Cancer Medicine (PCM) has been accepted for inclusion in Scopus.
As we prepare this brief 2020 annual report of Precision Cancer Medicine (PCM), the world is still in the fight against COVID-19 pandemic that has gravely impacted every aspects of our personal and professional lives for over a year.
AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020.
With a commitment to openness and accountability, and to increase the level of transparency throughout our peer review process, our editorial office has decided to implement a transparent peer review process as an option for all manuscripts submitted to PCM from March 19, 2020.
PCM Annual Report (2019)
Precision Cancer Medicine welcomes case reports which are supposed to report new observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the fields of medicine.
PCM Annual Report (2018)
Call for Papers - Focused Issue: Genomic Instability, Clonal Evolution and Oncogenesis
1 - 11 of 11 Items